December 16, 2011 / 12:27 PM / 7 years ago

UPDATE 1-Valeant antifungal drug meets late-stage goals

(Follows alerts)

Dec 16 (Reuters) - Canada’s Valeant Pharmaceuticals International Inc said its experimental antifungal drug met the main goals of two late-stage trials.

The company was testing its drug efinaconazole in two late-stage trials, as a treatment for fungal infections of the toenail.

Valeant said the drug was found to be statistically superior to placebo for all primary and secondary study goals.

Valeant shares closed at C$46.51 on Thursday on the Toronto Stock Exchange. (Reporting by Anand Basu in Bangalore; Editing by Esha Dey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below